Quantcast
Last updated on April 16, 2014 at 17:34 EDT

Latest Transition Therapeutics Inc. Stories

2013-09-11 16:25:20

TORONTO, Sept. 11, 2013 /PRNewswire/ - Transition Therapeutics Inc. ("Transition" or the "Company") (TSX: TTH; NASDAQ: TTHI), a product-focused biopharmaceutical company developing therapeutics for disease indications with large markets, today announced its financial results for the year ended June 30, 2013. Selected Highlights During fiscal 2013 and up to the date of this press release, the Company announced the following: ELND005: -- September 4, 2013 -...

2013-09-09 08:26:33

TORONTO, Sept. 9, 2013 /PRNewswire/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) will hold a conference call on Wednesday, September 11th, 2013 at 4:30 P.M. EST to discuss Full Year Fiscal 2013 financial results.   Dr. Tony Cruz, Chairman and Chief Executive Officer of the Company, will host the call. Transition will announce its financial results for this period in a press release to be issued prior to the call.  In order to participate...

2013-09-04 08:30:25

TORONTO, Sept. 4, 2013 /PRNewswire/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) announced the first patient dosing in a Phase 2a study of ELND005 in Down syndrome. Study ELND005-DS201 will evaluate the safety and pharmacokinetics of two doses of ELND005 and placebo in young adults with Down syndrome without dementia, and will also include select cognitive and behavioural measures. Information on the study design and protocol for...

2013-08-15 16:24:05

TORONTO, Aug. 15, 2013 /PRNewswire/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI) (TSX: TTH) announced that it has closed its previously announced private placement through which 2,625,300 units of the Company were purchased by Jack W. Schuler, Larry N. Feinberg, Oracle Investment Management, certain Transition Board members, management and other existing shareholders.   Gross proceeds of the private placement totalled US$11 million. As...

2013-08-02 08:24:49

Company to Receive Upfront US$11 Million Upon Closing TORONTO, Aug. 2, 2013 /PRNewswire/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) announced that Jack W. Schuler, Larry N. Feinberg, Oracle Investment Management, certain Transition Board members, management and other existing shareholders will make an investment of up to US$21 million by purchasing 2,625,298 units of the Company at a price of US$4.19 per common share. Each unit...

2013-07-23 16:24:28

TORONTO, July 23, 2013 /PRNewswire/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) today announced the exclusive licensing of worldwide rights to a novel small molecule transcriptional regulator ("TT-601") from Eli Lilly and Company for the treatment of osteoarthritis ("OA") pain.  TT-601 is a potent and selective ligand for a novel nuclear receptor target. Modulating the activity of this novel target in patients with osteoarthritis may...

2013-07-17 16:28:07

TORONTO, July 17, 2013 /PRNewswire/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) announced that the US Food and Drug Administration (FDA) has granted Fast Track Designation to the development program for ELND005 which was submitted for the treatment of Neuropsychiatric Symptoms (NPS) in Alzheimer's disease (AD). The FDA concluded that the development program for ELND005 for the treatment of NPS in AD meets their criteria for Fast Track...

2013-07-08 12:28:37

TORONTO, July 8, 2013 /PRNewswire/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) announced today that Dr. Tony Cruz, Chairman and Chief Executive Officer of Transition will be presenting at the 8(th) Annual JMP Securities Healthcare Conference on Tuesday, July 9th, 2013 at 3:00 p.m. Eastern Time at the St. Regis Hotel in New York City. About Transition Transition is a biopharmaceutical company, developing novel therapeutics for disease...

2013-06-17 08:27:20

TORONTO, June 17, 2013 /PRNewswire/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) announced that Eli Lilly and Company ("Lilly") has exercised its option to assume all development and commercialization rights to type 2 diabetes drug candidate TT-401.   In conjunction with this assumption of rights, Transition will receive a US$7 million milestone payment. Lilly and Transition have amended their agreement to address future...

2013-05-07 16:28:39

TORONTO, May 7, 2013 /PRNewswire/ - Transition Therapeutics Inc. ("Transition" or the "Company") (TSX: TTH; NASDAQ: TTHI), a product-focused biopharmaceutical company developing therapeutics for disease indications with large markets, today announced its financial results for the three and nine month periods ended March 31, 2013. Selected Highlights During fiscal 2013 and up to the date of this press release, the Company announced the following: -- On April 30, 2013,...